Literature DB >> 34763009

Role of chemerin in the control of glucose homeostasis.

A Léniz1, M González2, I Besné3, H Carr-Ugarte3, I Gómez-García3, M P Portillo4.   

Abstract

Chemerin is an adipokine produced by the white adipose tissue and other tissues, which plays various roles in the pathogenesis of inflammatory and metabolic diseases in multiple organs. The present review aims at gathering scientific evidence reported in the last ten years, concerning the relationship of chemerin with alterations of glycaemic control, such as insulin resistance, type 2 diabetes and gestational diabetes in humans. Although the vast majority of the studies have shown a positive correlation between the chemerin level and a bad glycaemic control, a general consensus has not been reached. The reported results come from case-control and observational longitudinal studies, thereby limiting their interpretation. In fact, it cannot be stated whether insulin resistance and diabetes lead to an increase in chemerin levels or, on the contrary, if high levels of chemerin contribute to an impaired glycaemic control. Elevated levels of circulating chemerin are also associated with gestational diabetes mellitus. Chemerin gene polymorphisms could be proposed as mediators of glucose-related diseases. Nevertheless, to date very little is known about their implication in glucose metabolism. With regard to the mechanisms of action, chemerin impairs insulin cascade signaling by acting on several proteins of this cascade and by inducing inflammation.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Chemerin; Gestational diabetes; Glycaemic control; Insulin resistance; Type 2 diabetes

Mesh:

Substances:

Year:  2021        PMID: 34763009     DOI: 10.1016/j.mce.2021.111504

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  5 in total

1.  The Chemerin-CMKLR1 Axis is Functionally important for Central Regulation of Energy Homeostasis.

Authors:  Haesung Yun; Rebecca Dumbell; Katie Hanna; Junior Bowen; Samantha L McLean; Sriharsha Kantamneni; Klaus Pors; Qing-Feng Wu; Gisela Helfer
Journal:  Front Physiol       Date:  2022-05-30       Impact factor: 4.755

2.  The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile.

Authors:  Alana Aragón-Herrera; Manuel Otero-Santiago; Laura Anido-Varela; Sandra Moraña-Fernández; Manuel Campos-Toimil; Tomás García-Caballero; Luis Barral; Estefanía Tarazón; Esther Roselló-Lletí; Manuel Portolés; Oreste Gualillo; Isabel Moscoso; Ricardo Lage; José Ramón González-Juanatey; Sandra Feijóo-Bandín; Francisca Lago
Journal:  Front Pharmacol       Date:  2022-02-02       Impact factor: 5.810

Review 3.  Chemerin Forms: Their Generation and Activity.

Authors:  Lei Zhao; Lawrence L Leung; John Morser
Journal:  Biomedicines       Date:  2022-08-19

4.  Anti-Tumoral Effect of Chemerin on Ovarian Cancer Cell Lines Mediated by Activation of Interferon Alpha Response.

Authors:  Meike Schmitt; Johanna Gallistl; Susanne Schüler-Toprak; Jürgen Fritsch; Christa Buechler; Olaf Ortmann; Oliver Treeck
Journal:  Cancers (Basel)       Date:  2022-08-25       Impact factor: 6.575

Review 5.  Chemerin: A Functional Adipokine in Reproductive Health and Diseases.

Authors:  Ming Yu; Yali Yang; Chen Huang; Lei Ge; Li Xue; Zhonglin Xiao; Tianxia Xiao; Huashan Zhao; Peigen Ren; Jian V Zhang
Journal:  Biomedicines       Date:  2022-08-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.